sign in sign up
<<
Home , Pneumococcal vaccine, Yellow fever vaccine

Vaccine Highlights IAC EXPRESS Recommendations, schedules, and more Get weekly updates Editor’s note: The information in High- In April, FDA published an update on distribution on vaccine information lights is current as of May 23, 2016. of yellow vaccine during the current short- while it’s still news! age. According to the FDA’s “CBER-Regulated All the news we publish in “Vaccine Products: Current Shortages” website, YF-VAX Highlights” will be sent by email to Next ACIP meetings ( Pasteur) is being provided only to custom- you every Wednesday. Free! ers who have patients planning to travel within The Advisory Committee on Practic- 30 days to an area where vaccine is To sign up for IAC Express – and any es (ACIP) is comprised of 15 national experts who required or recommended. This measure is neces- of our other free publications – visit advise CDC on the appropriate use of . sary to responsibly manage the limited U.S. supply ACIP meets three times a year in Atlanta; meet- of YF-VAX. To obtain vaccine, providers must www.immunize.org/subscribe ings are open to the public and viewable online via call (800-822-2463) and speak to a live webcast. The next meetings will be held on customer service representative. June 22–23 and Oct. 19–20. For more information, visit www.cdc.gov/vaccines/acip. ACIP periodically issues recommendations on CDC news Current VIS dates the use of vaccines; they are published and readily available in the Morbidity and Mortality Weekly CDC’s 47th National Immunization Conference Check the dates on your supply of Vaccine Report (MMWR). Clinicians who vaccinate should will be held Sept. 13–15, in Atlanta. For more Information Statements (VISs). If they are out have a current set for reference. Here are sources: information, visit www.cdc.gov/vaccines/events/ of date and need to be replaced, obtain the • Download from IAC’s website: www.immunize. nic/index.html. most up-to-date versions as well as VIS org/acip translations in more than 30 languages at • Download from CDC’s website: www.cdc.gov/ www.immunize.org/vis. vaccines/hcp/acip-recs Measles outbreak news Adenovirus...... 6/11/14 MMR...... 4/20/12 As of the time of this writing (May 10), the measles Anthrax...... 3/10/10 MMRV...... 5/21/10 VIS news outbreak in Shelby County (Memphis), Tennessee, Chickenpox...... 3/13/08 Multi-vaccine...... 11/5/15 stands at seven cases. On April 21, the Shelby DTaP...... 5/17/07 PCV13...... 11/5/15 On March 31, CDC released final versions of the County Health Department (SCHD) received con- Hib...... 4/2/15 PPSV...... 4/24/15 HPV9 ( 9) and the Meningococcal ACWY firmation of measles in two county resi- Hepatitis A...... 10/25/11 Polio...... 11/8/11 Vaccine Information Statements (VISs). Neither dents who both developed rash on April 9 and were ...... 2/2/12 Rabies...... 10/6/09 differs significantly from the previous VIS, but hospitalized briefly before recovering. The two HPV-...... 5/3/11 Rotavirus...... 4/15/15 both are now final, rather than interim, editions. local patients lived in different parts of the county HPV-Gardasil...... 5/17/13 Shingles...... 10/6/09 CDC encourages providers to begin using these and had no connection to one another; neither had HPV-Gardasil 9.....3/31/16 Td...... 2/24/15 VISs immediately, but stocks of the previous edi- traveled or reported contact with any ill travelers Influenza...... 8/7/15 Tdap...... 2/24/15 tions may still be used until supplies are exhausted. in the weeks prior to illness onset. Genotyping of Japanese enceph...1/24/14 Typhoid...... 5/29/12 The two new VISs, along with many translations, the suggested the same source. Since then, MCV4/MPSV4...... 3/31/16 Yellow fever..... 3/30/11 are available here: five additional persons have been diagnosed with MenB...... 8/14/15 • HPV 9 – www.immunize.org/vis/vis_hpv_ measles; four of the five were known contacts of  gardasil_9.asp the two initial cases. For a ready-to-print version of this table for • Meningococcal ACWY – www.immunize. The date of rash onset and isolation of the most posting in your practice, go to www.immunize. org/vis/vis_meningococcal_mcv_mpsv.asp recent case was May 4; known contacts to this case org/catg.d/p2029.pdf. To access all VISs in more than 35 languages, visit will be monitored through May 25. Of the cases, IAC’s VIS web section at www.immunize.org/vis. SCHD reports that six were unimmunized; one had

received one dose of vaccine. Pocket Guide SCHD, with assistance from the Tennessee Routine with PCV13 and PPSV FREE! Children: Administer pneumococcal (PCV13) to all infants and children at ages 2, 4, and 6 mos with a booster at age 12–15 mos. For incomplete or unvaccinated children, catch-up vaccination Department of Health, has followed up on hundreds should occur through age 59 mos. FDA vaccine news Adults age 65 years (or older): IAC’s Laminated Pocket • Administer a 1-time dose of PCV13 (if not previously received). • Administer a dose of pneumococcal polysaccharide vaccine (PPSV) of contacts exposed in healthcare and other settings. at least 1 yr after PCV13. Guides for Pneumococcal Risk-Based Vaccination with PCV13 and PPSV

A dose of PPSV is recommended for all people age 2 through 64 yrs with any of the following conditions: On April 14, FDA approved a change for Trumenba SCHD has set up a hotline for public calls, posted a. Cigarette smokers age 19 yrs and older and Zoster Vaccines b. Chronic cardiovascular disease (e.g., congestive heart failure, cardio- myopathy) c. Chronic pulmonary disease (including asthma in people age 19 yrs and older) MenB vaccine () to include a two-dose sched- measles educational information to its website, and d. Diabetes mellitus, alcoholism, or chronic liver disease e. Candidate for or recipient of cochlear implant Available in bulk f. Cerebrospinal fluid leak g. Functional or anatomic (e.g., sickle cell disease, splenectomy) h. Immunocompromising conditions (e.g., congenital or acquired begun auditing student records in area school sys- immunodeficiency, HIV infection, leukemia, lymphoma, Hodgkin ule (doses administered at 0 and 6 months) as well disease, generalized malignancy, iatrogenic , quantities. multiple myeloma, or on immunosuppressive therapy, including long-term systemic corticosteroids, radiation therapy) i. Solid organ transplantation; for bone marrow transplantation tems in preparation for the possibility of a school patients, see www.cdc.gov/vaccines/pubs/hemato-cell-transplts.htm as a modification of the three-dose schedule from j. Chronic renal failure or A second dose of PPSV is recommended for children and adults through Order online: age 64 yrs who are at highest risk of serious pneumococcal disease or likely to have a rapid decline in pneumococcal antibody levels (categories administration at 0, 2, and 6 months to administra- exposure. Education efforts also have been aimed g–j above) at least 5 yrs after dose #1. Note: Administer an additional dose of PPSV to all adults at age 65 yrs www.immunize.org/ (or older). Give it at least 5 yrs after any previous PPSV. A 1-time dose of PCV13 is recommended for previously unvaccinated people age 6 through 64 yrs who meet any of the criteria in categories tion at 0, 1–2, and 6 months. Trumenba is approved at ensuring healthcare providers recognize and re- e–j above. pocketguides Created by the Immunization Action Coalition (www.immunize.org) Item #R2203 (1/16) for use in individuals age 10 through 25 years for spond properly to a suspected measles case and that Supported by an educational grant from Merck. to prevent invasive disease they have appropriate documentation of immunity caused by Neisseria meningitidis serogroup B. to measles before an occupational exposure occurs. The updated package insert is available at http:// For more information, visit www.schdresponse. labeling.pfizer.com/ShowLabeling.aspx?id=1796. com/content/measlesoutbreak. ✦

Vaccinate Adults! • May 2016 • Immunization Action Coalition • (651) 647-9009 • www.immunize.org • www.vaccineinformation.org 5